Companies Attending the 10th Anniversary Include: Madrigal Pharmaceuticals, Arda Therapeutics, Tribune Therapeutics, AbbVie, aTyr Pharma, Pfizer and lots more - View the Full Event Guide Breakdown

United Therapeutics Moves Toward the First Inhaled Antifibrotic for IPF

Insilico Medicine's rentosertib (INS018_055) has entered Phase III development for IPF

Skye Bioscience and Redx Pharma announced plans to form fibrosis-focused Fibrx Therapeutics

Global interest continues to surge following Eli Lilly's $630 million licensing deal with OliX Pharmaceuticals for the MASH/obesity cross-indication asset OLX702A

Yuhan Develops Anti-Fibrosis Drug Candidate, Wins U.S. Patent

Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets

Register Before Friday, October 16 & Save up to $600

Day

Hour

Minute

Second

Developing Cross-Indication Strategies to Maximize the Clinical & Commercial Potential of Antifibrotic Therapies

Developing Cross-Indication Strategies to Maximize the Clinical & Commercial Potential of Antifibrotic Therapies

Developing Cross-Indication Strategies to Maximize the Clinical & Commercial Potential of Antifibrotic Therapies

Venue

Map

Contact

Join Our Team

About Us

Explore Our Conferences

Stay Connected

Search

Organized By